DRUG NAME MECHANISM OF ACTION INDICATION / ADVERSE EFFECT NURSING RESPONSIBILITIES

CONTRAINDICATION

GENERIC: INDICATIONs: CNS: BEFORE:

Ferrous Sulfate Iron combines with porphyrin and -Iron deficiency anemia, blood loss hyperventilation Dx:
BRAND: globin chains to form hemoglobin, related to pregnancy or GI bleeding GI: a. Assess for clinical
low FE, Fer-In-Sol, Feratab, Iron, which is critical for oxygen delivery (NSAIDs), hookworm infestation, or Diarrhea, vomiting, dehydration, improvement, record relief
Mol-Iron, Feosol, MyKidz Iron 10 from the lungs to other tissues. Iron excess coffee peptic ulcer, regional enteritis, of iron deficiency
CLASS: deficiency causes a microcytic ulcerative colitis symptoms (fatigue,
anemia due to the formation of small CONTRAINDICATION: DERM: irritability, pallor,
THERAPEUTIC erythrocytes with insufficient -Hypersensitivity to iron salts. Pallor, cyanosis paresthesia of extremities,
IRON SUPPLEMENT hemoglobin. Hemochromatosis, hemolytic ENDO: headache)
PHARMACOLOGIC: anemias. Cautions: Peptic ulcer, Diabetes, severe abdominal pain b. Assess for history of seizure
-An oral (absorbable) iron Source: regional enteritis, ulcerative NEURO: disorders.
formulation. Zehnder JL (2021): Agents Used in cardiovascular collapse c. Check for allergies.
colitis, pts receiving frequent
-Replenishes Iron Cytopenias; Hematopoietic Growth d. Assess baseline mental
Factors. (Chapter 33). In: Basic & blood transfusions. status
DOSAGE: Clinical Pharmacology. 15e. e. Monitor daily pattern of
-220mg (44mg Fe)/5mL Katzung BG, Vanderah TW DRUG TO DRUG bowel activity, stool
-300mg (60mg Fe)/5mL (adult only) (Editors). McGraw-Hill / Lange. INTERACTION: consistency.
-15 mg elemental Fe/mL (Access-Medicine)McGraw-Hill / Moderate Interactions of Ferrous Tx:
Lange. (Access-Medicine) Sulfate: a. Supervise patients at risk
ROUTE: - Calcium 600 D for suicide closely during
ORAL - Nexium initial therapy.
- Synthroid b. Perform a thorough
Serious Interactions of ferrous physical assessment to
sulfate include: establish baseline data
-demeclocycline before drug therapy begins,
-dolutegravir to determine the
-doxycycline effectiveness of therapy,
-eltrombopag and to evaluate for the
-fleroxacin occurrence of any adverse
-gemifloxacin effects associated with drug
-levofloxacin therapy.
-lymecycline c. Restrict amount of drug
-minocycline available to patient.
-moxifloxacin d. Periodically assess dose.
-mycophenolate EDx:
-norfloxacin a. Instruct pt. to take
-ofloxacin sertraline as directed
-oxytetracycline b. Caution pt. that drowsiness
-tetracycline or dizziness may occur.
c. Educate client on drug
DRUG TO FOOD therapy to promote
INTERACTION: compliance.
- Alcohol d. Insure the patient takes the
medication as prescribed.

DURING:
Dx:
a. Asses mental status for
worsening of depression,
anxiety, social functioning,
and or panic attack
b.
c. Assess for clinical
improvement, record relief
of iron deficiency
symptoms (fatigue,
irritability, pallor,
paresthesia of extremities,
headache)Monitor serum
iron, total iron-binding
capacity, reticulocyte count,
Hgb, ferritin.
d. Monitor mood changes.
e. Monitor for adverse effects
(e.g. cardiovascular
collapse, diabetes, severe
abdominal pain,
 hyperventilation etc).
f. Check for drug or herbal
interactions
g. monitor hemoglobin,
hematocrit, iron levels
h.
Tx:
a.
Limit drug access if patient
is suicidal to decrease the
risk of overdose to cause
harm.
b. Administer a major portion
of dose at bedtime as
ordered if drowsiness and
anticholinergic effect are
severe to decrease the risk
of patient injury.
c. Establish suicide
precautions for severely
depressed patients to
decrease the risk of
overdose to cause harm.
d. Assist pt. in taking the
medication.
EDx:
a. Instruct pt. SO to report
diarrhea, nausea, dyspepsia,
insomnia, drowsiness,
dizziness, or persistent
headache to physician.
b. Report diarrhea, nausea,
dyspepsia, insomnia,
drowsiness, dizziness, or
persistent headache to
physician.
 c.
Inform of drugs and herbs
that can interact
d. Instruct patient to verbalize
feelings and concerns.
AFTER:
Dx:

a. Assess for clinical

improvement, record relief
of iron deficiency
symptoms (fatigue,
irritability, pallor,
paresthesia of extremities,
headache)
b. Assess knowledge/teach
patient appropriate use
,interventions to reduce side
effects, and adverse
symptoms to report
c. Monitor for effectiveness as
exhibited by a decrease in
symptoms
d. Monitor for side effects.
e. Assess for serotonin
syndrome
Tx:
a. Remember that a lot of
these drugs can cause
dizziness in the first few
weeks of taking so take
safety precautions.
b. Provide safety measures
(e.g. adequate lighting,
raised side rails, etc.) to
prevent injuries.
 c.Provide comfort measures
(e.g. voiding before dosing,
taking food with drug, etc.)
to help patient tolerate drug
effects.
d. Administer drug once a day
in the evening to achieve
optimal therapeutic effects.
EDx:
a. Monitor patient compliance
to drug therapy.
b. Monitor patient for 2-4
weeks to ascertain onset of
full therapeutic effect.
c. Advise pt. to avoid alcohol
intake.
d. Instruct patient to verbalize
feelings and concerns.

categorize your NURSING RESPONSIBILITIES as to Before, During and After giving the medication and each has Dx, Tx and EDx.